山东大学学报 (医学版) ›› 2020, Vol. 58 ›› Issue (6): 47-52.doi: 10.6040/j.issn.1671-7554.0.2019.1452
• • 上一篇
王冰玉,杨阳,晁岚
WANG Bingyu, YANG Yang, CHAO Lan
摘要: 目的 探讨TOLL样受体4(TLR4)在子宫腺肌病发病中的作用及其与凋亡的关系。 方法 Western blotting检测TLR4蛋白在子宫腺肌病患者内膜组织和对照组正常子宫内膜中表达水平;Real-time PCR检测TLR4 mRNA在子宫腺肌病患者子宫内膜组织和对照组正常子宫内膜中表达水平;免疫组织化学染色法检测子宫腺肌病患者子宫内膜组织和对照组正常子宫内膜中TLR4的表达及定位情况;TUNEL检测子宫腺肌病患者子宫内膜组织和对照组正常子宫内膜的细胞凋亡水平;通过脂多糖(LPS)激活h-ESC细胞系,使细胞系中的TLR4的表达升高,流式细胞术检测凋亡水平,由此验证TLR4对细胞凋亡的作用。 结果 Western blotting 结果显示TLR4的蛋白表达水平在子宫腺肌病子宫内膜组织中较对照组降低(P=0.0182),Real-time PCR结果显示TLR4的mRNA表达水平在子宫腺肌病子宫内膜组织中较对照组降低(P=0.0197),免疫组织化学染色法结果显示TLR4主要位于子宫内膜组织和对照组正常子宫内膜中的腺上皮细胞质中表达,且子宫腺肌病患者子宫内膜组织中TLR4的表达水平较对照组降低(P=0.0160)。TUNEL结果显示子宫腺肌病内膜细胞中细胞凋亡较对照组降低(P=0.0024),h-ESC细胞系中TLR4被成功激活后,流式细胞术显示右下象限细胞所占比例升高,表明细胞凋亡水平升高。 结论 TLR4可能通过调控细胞凋亡在子宫腺肌病的发生发展中发挥作用。
中图分类号:
[1] Pontis A, DAlterio MN, Pirarba S, et al. Adenomyosis: a systematic review of medical treatment [J]. Gynecol Endocrinol, 2016, 32(9): 696-700. [2] Nikkanen V, Punnonen R. Clinical significance of adenomyosis [J]. Ann Chir Gynaecol, 1980, 69(6): 278-280. [3] Ota H, Igarashi S, Hatazawa J, et al. Is adenomyosis an immune disease [J] Hum Reprod Update, 1998, 4(4): 360-367. [4] Munro MG. Uterine polyps, adenomyosis, leiomyomas, and endometrial receptivity [J]. Fertil Steril, 2019, 111(4): 629-640. [5] Liu Y, Tan X, Wang Z, et al. Down-regulation of tumor suppressor PDCD4 expression in endometrium of adenomyosis patients [J]. Curr Res Transl Med, 2016, 64(3): 123-128. [6] Buggio L, Monti E, Gattei U, et al. Adenomyosis: fertility and obstetric outcome. A comprehensive literature review[J]. Minerva Ginecol, 2018, 70(3): 295-302. [7] Orazov MR, Nosenko EN, Radzinsky VE, et al. Proangiogenic features in chronic pelvic pain caused by adenomyosis [J]. Gynecol Endocrinol, 2016, 32(sup2): 7-10. [8] Vannuccini S, Tosti C, Carmona F, et al. Pathogenesis of adenomyosis: an update on molecular mechanisms [J]. Reprod Biomed Online, 2017, 35(5): 592-601. [9] Kvaskoff M, Mu F, Terry KL, et al. Endometriosis: a high-risk population for major chronic diseases? [J]. Hum Reprod Update, 2015, 21(4): 500-516. [10] Mu F, Rich-Edwards J, Rimm EB, et al. Endometriosis and risk of coronary heart disease [J]. Circ Cardiovasc Qual Outcomes, 2016, 9(3): 257-264. [11] Kishi Y, Shimada K, Fujii T, et al. Phenotypic characterization of adenomyosis occurring at the inner and outer myometrium[J]. PLoS One, 2017, 12(12): e0189522. doi:10.1371/journal.pone.0189522. [12] Aznaurova YB, Zhumataev MB, Roberts TK, et al. Molecular aspects of development and regulation of endometriosis [J]. Reprod Biol Endocrinol, 2014, 12: 50. doi:10.1186/1477-7827-12-50. [13] Elmore S. Apoptosis: a review of programmed cell death [J]. Toxicol Pathol, 2007, 35(4): 495-516. [14] Pistritto G, Trisciuoglio D, Ceci C, et al. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies [J]. Aging(Albany NY), 2016, 8(4): 603-619. [15] Agui T, McConkey DJ, Tanigawa N. Comparative study of various biological parameters, including expression of survivin, between primary and metastatic human colonic adenocarcinomas [J]. Anticancer Res, 2002, 22(3): 1769-1776. [16] Khan KN, Masuzaki H, Fujishita A, et al. Immunoexpression of hepatocyte growth factor and c-Met receptor in the eutopic endometrium predicts the activity of ectopic endometrium [J]. Fertil Steril, 2003, 79(1): 173-181. [17] Harada M., Suganuma N, Furuhashi M, et al. Detection of apoptosis in human endometriotic tissues [J]. Mol Hum Reprod, 1996, 2(5): 307. [18] Afkham A, Eghbal-Fard S, Heydarlou H, et al. Toll-like receptors signaling network in pre-eclampsia: An updated review [J]. J Cell Physiol, 2019, 234(3): 2229-2240. [19] Azam S, Jakaria M, Kim LS, et al. Regulation of toll-like receptor(TLR)signaling pathway by polyphenols in the treatment of age-linked neurodegenerative diseases: focus on TLR4 signaling [J]. Front Immunol, 2019, 10: 1000. doi:10.3389/fimmu.2019.01000. [20] Karaffov a V, Marcinkov a E, Bobikov a K, et al. TLR4 and TLR21 expression, MIF, IFN-beta, MD-2, CD14 activation, and sIgA production in chickens administered with EFAL41 strain challenged with campylobacter jejuni[J]. Folia Microbiol(Praha), 2017, 62(2): 89-97. [21] Hu L, Yang H, Ai M, et al. Inhibition of TLR4 alleviates the inflammation and apoptosis of retinal ganglion cells in high glucose [J]. Graefes Arch Clin Exp Ophthalmol, 2017, 255(11): 2199-2210. [22] Everts B, Amiel E, Huang SC, et al. TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKvarepsilon supports the anabolic demands of dendritic cell activation [J]. Nat Immunol, 2014, 15(4): 323-332. [23] Zhao L, Ma R, Zhang L, et al. Inhibition of HIF-1a-mediated TLR4 activation decreases apoptosis and promotes angiogenesis of placental microvascular endothelial cells during severe pre-eclampsia pathogenesis [J]. Placenta, 2019, 83: 8-16. doi:10.1016/j.placenta.2019.06.375. [24] Chen W, Qian L, Wu F, et al. Significance of toll-like receptor 4 signaling in peripheral blood monocytes of pre-eclamptic patients [J]. Hypertens Pregnancy, 2015, 34(4): 486-494. [25] 熊小琴, 布占红, 朱虹, 等. 部分与全部子宫内膜电切术治疗子宫腺肌症临床疗效观察[J]. 中国研究型医院, 2018, 5(5): 41-43. XIONG Xiaoqin, BU Zhanhong, ZHU Hong, et al. Clinical efficacy of partial and total endometrial resection for adenomyosis [J]. Journal of Chinese Research Hospitals, 2018, 5(5): 41-43. [26] Pontis AD, Alterio MN, Pirarba S, et al. Adenomyosis: a systematic review of medical treatment [J]. Gynecol Endocrinol, 2016, 32(9): 696-700. |
[1] | 张士宝 刘庆勇 阮喜云 陈杰 张建军 李宗武 杨广笑 王全颖. NT4-SAC-HA2-TAT融合基因表达载体的构建及鉴定[J]. 山东大学学报(医学版), 2209, 47(6): 15-19. |
[2] | 鹿向东 杨伟 徐广明 曲元明. 脑膜瘤中PPAR-γ的表达及曲格列酮对脑膜瘤培养细胞生长的影响[J]. 山东大学学报(医学版), 2209, 47(6): 65-. |
[3] | 颜磊,岳彩欣,刘懿淳. 子宫内膜异位症的生育力保护[J]. 山东大学学报 (医学版), 2022, 60(9): 31-34. |
[4] | 鹿群,赵璐璐. 子宫内膜癌、子宫内膜非典型增生保留生育功能后助孕策略[J]. 山东大学学报 (医学版), 2022, 60(9): 35-41. |
[5] | 赵舸,邹存华,宋冬冬,赵淑萍. 丹参酮IIA对子宫内膜癌细胞增殖与凋亡的影响[J]. 山东大学学报 (医学版), 2022, 60(9): 53-58. |
[6] | 邹品衡,陈添果,胡康,李伟才. 过表达miR-27a对急性脑梗死大鼠海马神经元损伤的影响及其机制[J]. 山东大学学报 (医学版), 2022, 60(9): 59-66. |
[7] | 刘腾,马迎春. 基于生物信息库病例分析ECT2在子宫内膜癌中的表达及临床意义[J]. 山东大学学报 (医学版), 2022, 60(8): 63-71. |
[8] | 张信美,徐萍. 子宫腺肌病的手术治疗策略[J]. 山东大学学报 (医学版), 2022, 60(7): 26-31. |
[9] | 易晓芳,黄季华. 子宫腺肌病的患者教育及全程管理[J]. 山东大学学报 (医学版), 2022, 60(7): 32-35. |
[10] | 彭超,周应芳. 子宫腺肌病的药物治疗进展[J]. 山东大学学报 (医学版), 2022, 60(7): 20-25. |
[11] | 艾星子·艾里,郭铮宇,张晓霏. 子宫腺肌病高强度聚焦超声消融治疗研究进展[J]. 山东大学学报 (医学版), 2022, 60(7): 36-42. |
[12] | 郭孙伟,刘惜时. 子宫腺肌病发病机制和病理生理研究进展[J]. 山东大学学报 (医学版), 2022, 60(7): 6-19. |
[13] | 冷金花,史精华. 子宫腺肌病的临床表现[J]. 山东大学学报 (医学版), 2022, 60(7): 1-5. |
[14] | 陶国伟,王芳,董向毅,徐亚瑄,赵琳丽,胡蓓蓓. 子宫腺肌病的超声与MRI诊断及进展[J]. 山东大学学报 (医学版), 2022, 60(7): 56-65. |
[15] | 王国云,潘臧钰. 子宫腺肌病动物模型研究进展[J]. 山东大学学报 (医学版), 2022, 60(7): 48-55. |
|